Highlights
- The EAT-Lancet planetary health diet is nutritionally adequate for most micronutrients in population-based settings, though it poses an increased risk of anemia for women.
- The neoadjuvant PAXG quadruplet chemotherapy regimen significantly improves event-free survival (EFS) compared to mFOLFIRINOX in resectable and borderline resectable pancreatic ductal adenocarcinoma (PDAC).
- Inhalational methoxyflurane has been proven non-inferior to intravenous morphine and superior to intranasal fentanyl for rapid prehospital pain relief.
- Standardization of dietary scoring and energy adjustment is critical for interpreting the health impacts of sustainable nutrition frameworks.
Background
Modern clinical medicine is currently navigating a complex intersection of environmental sustainability, aggressive oncological interventions, and optimized emergency protocols. As the global healthcare community shifts toward evidence-based strategies that address both individual patient outcomes and broader public health challenges, three distinct domains have seen transformative evidence emerge in late 2024 and early 2025: sustainable nutrition, neoadjuvant surgical oncology, and non-invasive emergency analgesia.
The EAT-Lancet Commission’s planetary health diet was designed to reconcile human health with environmental limits, yet its practical nutritional adequacy has remained a subject of intense debate. Simultaneously, in the realm of oncology, pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, necessitating a shift from ‘surgery-first’ to more potent neoadjuvant systemic therapies. Finally, the prehospital environment continues to struggle with the ‘pain management gap,’ where traditional intravenous opioids are often delayed due to the logistical challenges of vascular access. This review synthesizes high-impact findings from the Malmö Diet and Cancer cohort, the CASSANDRA phase 3 trial, and the PreMeFen trial to provide clinicians with a multifaceted update on these evolving standards of care.
Key Content
1. Nutritional Adequacy and the EAT-Lancet Planetary Health Diet
The EAT-Lancet diet emphasizes a high intake of plant-based foods (fruits, vegetables, legumes, whole grains, and nuts) while permitting low-to-moderate consumption of seafood, poultry, and dairy, and minimal red meat. While environmental benefits are well-documented, physiological adequacy is paramount for clinical recommendation.
Methodological Nuances in Dietary Assessment
A Swedish population-based cohort study involving 25,970 participants from the Malmö Diet and Cancer cohort (PMID: 41692025) recently evaluated nutrient adequacy using seven different scoring frameworks. A critical finding was that the method of measuring adherence—specifically the use of energy adjustment—significantly impacts the perceived nutritional profile of the diet. Energy adjustment increased the likelihood of participants reaching recommended intakes for a broad spectrum of vitamins (A, E, C, B6, B12, and folate) and minerals (calcium, magnesium, potassium, iron, and zinc).
Biomarker Validation and Gender-Specific Risks
Unlike previous simulation-based models, this study integrated biomarker data for folate, vitamin D, selenium, and zinc. High adherence was strongly correlated with a reduced risk of folate deficiency. However, a significant clinical caveat emerged regarding iron status: higher adherence was associated with a slightly increased risk of anemia specifically in women. This likely reflects the lower bioavailability of non-heme iron and the restrictive nature of red meat consumption in the EAT-Lancet framework. Conversely, men showed a slightly lower risk of vitamin D deficiency at higher adherence levels, potentially due to the inclusion of fortified plant-based alternatives or seafood components.
2. Neoadjuvant PAXG vs. mFOLFIRINOX in Pancreatic Cancer
For patients with resectable and borderline resectable PDAC, the standard of care has gravitated toward neoadjuvant chemotherapy to improve R0 resection rates and address occult micrometastases. The CASSANDRA (PACT-21) trial (PMID: 41275879) represents a major leap in this domain, comparing the quadruplet PAXG regimen (cisplatin, nab-paclitaxel, capecitabine, and gemcitabine) against the previous benchmark, mFOLFIRINOX.
Survival Outcomes and Efficacy
The trial’s first randomization analysis revealed that PAXG significantly prolonged median event-free survival (EFS) to 16.0 months, compared to 10.2 months in the mFOLFIRINOX arm. The hazard ratio (HR) of 0.63 (95% CI 0.47-0.84; p=0.0018) suggests a 37% reduction in the risk of disease progression, recurrence, or death. This is particularly notable given that mFOLFIRINOX has long been considered the most potent available regimen.
Safety and Clinical Implementation
The intensity of quadruplet therapy naturally raises concerns regarding toxicity. Grade 3 or worse adverse events were observed in 66% of the PAXG group and 61% of the mFOLFIRINOX group. While the toxicity profiles are high, they are comparable between the two arms, suggesting that for fit patients (median age ~64 in the study), PAXG offers a superior benefit-to-risk ratio. The investigators concluded that preoperative PAXG should now be considered a new standard comparator for future clinical trials in the neoadjuvant setting.
3. Optimizing Prehospital Analgesia: The PreMeFen Trial
Acute traumatic or medical pain in the prehospital setting is frequently undertreated. The PreMeFen trial (PMID: 41275876) addressed this by comparing three distinct routes of administration: inhalational methoxyflurane, intranasal (IN) fentanyl, and intravenous (IV) morphine.
Comparative Efficacy at 10 Minutes
In this randomized, non-inferiority trial of 338 patients, methoxyflurane demonstrated a mean Numeric Rating Scale (NRS) reduction of -3.31, which was statistically non-inferior to both morphine (-2.74) and fentanyl (-1.98). Notably, intranasal fentanyl failed to meet the non-inferiority margin compared to morphine at the 10-minute mark, suggesting that the inhalational route provides more rapid and effective analgesia than the intranasal route in early ambulance care.
Safety and Adverse Events
Adverse event rates were balanced across groups (~22-24%). While methoxyflurane was generally well-tolerated, the trial recorded one instance of respiratory depression and loss of consciousness in that group, emphasizing that even non-opioid inhalants require vigilant monitoring. Nevertheless, the ease of administration makes methoxyflurane a primary candidate for ‘bridging’ pain management until definitive IV access or long-acting analgesics can be administered.
Expert Commentary
The Paradox of Sustainable Nutrition
The findings from the Swedish cohort emphasize that ‘healthy for the planet’ is not automatically ‘perfect for the individual’ without careful monitoring. The increased risk of anemia in women adhering to EAT-Lancet suggests that clinicians must recommend targeted supplementation or focus on enhancing iron absorption (e.g., combining plant-based iron with vitamin C) when patients transition to plant-forward diets. The variation in outcomes across different scoring methods also highlights a desperate need for a ‘standardized nutritional metric’ in research to prevent fragmented or contradictory guidelines.
Escalating Systemic Therapy in PDAC
The success of the PAXG regimen in the CASSANDRA trial reflects a broader trend in oncology toward ‘total neoadjuvant therapy.’ By utilizing four drugs with different mechanisms of action—platinum-based DNA damage (cisplatin), microtubule inhibition (nab-paclitaxel), antimetabolites (gemcitabine), and fluoropyrimidines (capecitabine)—the regimen effectively tackles the heterogeneity of pancreatic tumors. However, the high rate of Grade 3 toxicities means that patient selection (performance status and CA 19-9 levels) remains the most critical task for the multidisciplinary team.
The Shift Toward Non-Invasive Emergency Care
The PreMeFen trial results challenge the traditional ‘IV Morphine First’ dogma. In the chaotic environment of an ambulance, the 10 minutes saved by avoiding a difficult IV start can be the difference between humanitarian pain relief and prolonged suffering. Methoxyflurane’s performance suggests it should be a first-line consideration for paramedics, particularly in trauma where rapid onset is essential.
Conclusion
The clinical landscape in 2025 is marked by a drive toward higher potency and greater precision. In nutrition, the EAT-Lancet diet provides a robust micronutrient framework but requires vigilance regarding iron status in women. In oncology, the PAXG regimen has redefined the ceiling for neoadjuvant efficacy in pancreatic cancer, offering nearly six months of additional event-free survival over mFOLFIRINOX. In emergency medicine, inhalational methoxyflurane has emerged as a superior non-invasive analgesic compared to intranasal options. Future research must now focus on the long-term sustainability of these intensive interventions and the development of personalized protocols to mitigate their respective risks.
References
- Malmö Diet and Cancer Study Group. Nutritional adequacy of the EAT-Lancet diet: a Swedish population-based cohort study. Lancet Planet Health. 2025;9:101416. PMID: 41692025.
- CASSANDRA Investigators. Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma: results of a randomised phase 3 trial. Lancet. 2026;406(10522):2945-2956. PMID: 41275879.
- PreMeFen Trial Group. Comparison of inhalational methoxyflurane, intranasal fentanyl, and intravenous morphine for treatment of prehospital acute pain in Norway: a randomised phase 3 trial. Lancet. 2026;406(10522):2957-2967. PMID: 41275876.